McConnell’s absence could jeopardize Republicans’ defense spending agenda as the Iran war escalates

Sen. Mitch McConnell was hospitalized after a fall and treated for pneumonia, and Sen. Lindsey Graham died unexpectedly, complicating Senate Republican efforts to pass FY2027 spending—where the defense base is $1.15T and the Trump goal is a $1.5T defense budget. With the Senate Appropriations defense panel stuck at a 14-14 split, a defense appropriations bill is unlikely to reach the floor, just as Congress races toward the Sept. 30 fiscal-year funding deadline and the administration seeks a $350B Iran supplemental via reconciliation (51-vote path vs 60). Political risk is elevated by the midterms and war urgency, with estimates placing Iran-war costs at $113B already and potentially over $1T, and munitions stocks cut by more than half.

Analysis

The market takeaway is less about higher defense demand and more about timing risk: when appropriations get bottlenecked, the first casualty is not prime contractor revenue but the pace of new starts, munitions replenishment, and working-capital turns for lower-tier suppliers. That creates a split: large incumbents with backlog and international exposure should absorb a CR better, while smaller, budget-sensitive names and suppliers tied to missile defense, ammo, and rapid replenishment face multiple compression if the funding path slips into the post-midterm window.

The second-order effect is that the longer Congress drags its feet, the more the administration’s defense narrative becomes a political trade rather than an earnings trade. If the procedural path breaks before Sept. 30, defense equities could get a knee-jerk bid on headline urgency; if it doesn’t, the consensus will have to mark down 2026 growth assumptions tied to supplemental war funding and ‘Golden Dome’ style add-ons. That is the real risk: not a collapse in demand, but a slide from expected acceleration to deferred spending, which is usually worse for valuation than for near-term revenue.

Contrarian view: investors may be overestimating how much of the defense theme is already secured by geopolitics. The Senate bottleneck means a lot of the headline spending is still optionality, not cash flow. Until there is committee passage or a credible reconciliation vehicle, the trade is more about relative positioning than outright beta.

Key Decisions for Investors

• Prefer long LMT/RTX vs short XAR for the next 4-8 weeks: primes should hold up better under a CR, while equal-weight/smaller-cap defense gets hit harder by delayed awards and procurement timing.
• Avoid chasing the defense-spending headline in small-cap suppliers until there is proof of committee progress; if you want exposure, wait for a real catalyst (markup, recess cancellation, or a cleared reconciliation vote) and then use ITA call spreads expiring after Sept. 30.
• Keep a tactical short bias on high-duration defense/munitions baskets if the Senate heads into August recess without a funding breakthrough; thesis is vulnerable only if leadership cancels recess or secures 51 votes for reconciliation.
• No high-conviction action in CATO/DJT/GHM/TSTS from this item alone; they are weak read-through vehicles until the article’s funding mechanics translate into actual contract or budget changes.